Construction of a core-shell microneedle system to achieve targeted co-delivery of checkpoint inhibitors for melanoma immunotherapy
Source abstract
Abstract
Synergistic anti-tumor effect of anti-PD-1/L1 antibody (aPD-1/aPD-L1) and 1-methyl-D,L-tryptophan (1-MT) in melanoma has been well demonstrated, while efficient topical delivery systems are still largely unexplored. Here, a highly drug-concentrated hybrid core-shell microneedle (CSMN) system for co-delivery of checkpoint inhibitors was developed. Based on the specific drug-matrix interaction, the system concentrated aPD-L1 in the tips of microneedles through electrostatic interactions, and increased the amount of 1-MT loaded in CSMN by preventing its premature crystallization using PVA, the material used to prepare CSMN core. The prepared CSMN exhibited high transdermal delivery efficiency and long topical retention time of aPD-L1 for 2 days. Drug-loaded CSMN achieved better anti-tumor efficacy than the intra-tumor injection group at the same dose, which was likely because the former recruited more T lymphocytes to the tumor site. These findings suggested that this CSMN system was a promising local delivery system of both aPD-L1 and 1-MT for melanoma immunotherapy, and its unique core-shell structure could be readily adapted as a modular platform for various diseases, where combination therapy of both biomacromolecular drugs and other small-molecular agents were required. STATEMENT OF SIGNIFICANCE: In the present study, a core-shell microneedle (CSMN) system was constructed to achieve targeted co-delivery of checkpoint inhibitors to melanoma, while preventing significant systemic exposure. To overcome the drawback of insufficient drug loading of microneedles and effectively encapsulate two drugs simultaneously, microneedles were divided into two independent functional areas, a charged shell and a hydrophilic core and encapsulated drugs based on respective drug-matrix interaction. The charged shell prepared by chitosan could concentrate aPD-L1 in the tips of microneedles through electrostatic interactions. The core prepared by PVA successfully increased the amount of 1-MT loaded in microneedles by preventing its premature crystallization. The prepared CSMN exhibited high transdermal delivery efficiency and better anti-tumor efficacy than intra-tumor injection at the same dose.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Immunotherapy and Immune Responses · Monoclonal and Polyclonal Antibodies Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (35)
Show source-provided references
1. Cancer incidence and mortality worldwide: sources, methods and major patterns in globocan 201210.1002/ijc.29210 ↗
2. Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries10.3322/caac.21492 ↗
3. Strategies to improve the efficacy of dendritic cell-based immunotherapy for melanoma10.3389/fimmu.2017.01594 ↗
4. Advances in proteomic techniques for cytokine analysis: focus on melanoma research10.3390/ijms18122697 ↗
5. PD-1 and its ligands in tolerance and immunity10.1146/annurev.immunol.26.021607.090331 ↗
6. PD-1 as a potential target in cancer therapy10.1002/cam4.106 ↗
7. New insights into cancer immunoediting and its three component phases–elimination, equilibrium and escape10.1016/j.coi.2014.01.004 ↗
8. PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies10.1016/j.humpath.2017.06.012 ↗
9. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations10.3389/fonc.2018.00086 ↗
10. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome
11. Targeting the indoleamine 2,3-dioxygenase pathway in cancer10.1186/s40425-015-0094-9 ↗
12. Pembrolizumab versus ipilimumab in advanced melanoma10.1056/NEJMoa1503093 ↗
13. Checkpoint inhibitors in melanoma and early phase development in solid tumors: what's the future?10.1186/s12967-017-1278-5 ↗
14. Rationale for new checkpoint inhibitor combinations in melanoma therapy10.1007/s40257-017-0282-0 ↗
15. Indoximod: an immunometabolic adjuvant that empowers t cell activity in cancer
16. Phase 2 trial of the ido pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma
17. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer10.1056/NEJMoa1200690 ↗
18. Permeation enhancer strategies in transdermal drug delivery10.3109/10717544.2014.935532 ↗
19. Microneedle-array patches loaded with dual mineralized protein/peptide particles for type 2 diabetes therapy10.1038/s41467-017-01764-1 ↗
20. Phase-transition microneedle patches for efficient and accurate transdermal delivery of insulin10.1002/adfm.201500554 ↗
21. Insulin-responsive glucagon delivery for prevention of hypoglycemia10.1002/smll.201603028 ↗
22. Microneedle patches for vaccination in developing countries10.1016/j.jconrel.2015.11.019 ↗
23. Au nanocage-strengthened dissolving microneedles for chemo-photothermal combined therapy of superficial skin tumors10.1021/acsami.7b18293 ↗
24. Composite-dissolving microneedle patches for chemotherapy and photothermal therapy in superficial tumor treatment10.1039/C8BM00005K ↗
25. Near-infrared light-activatable microneedle dystem for treating superficial tumors by combination of chemotherapy and photothermal therapy10.1021/acsnano.5b05043 ↗
26. Enhanced cancer immunotherapy by microneedle patch-assisted delivery of anti-PD1 antibody10.1021/acs.nanolett.5b05030 ↗
27. Synergistic transcutaneous immunotherapy enhances antitumor immune responses through delivery of checkpoint inhibitors10.1021/acsnano.6b04989 ↗
28. Investigation on fabrication process of dissolving microneedle arrays to improve effective needle drug distribution10.1016/j.ejps.2014.09.011 ↗
29. Novel dissolving microneedles for enhanced transdermal delivery of levonorgestrel: in vitro and in vivo characterization10.1016/j.ijpharm.2017.10.035 ↗
30. Drug precipitation inhibitors in supersaturable formulations10.1016/j.ijpharm.2013.05.013 ↗
31. Anti-obesity effect of a novel caffeine-loaded dissolving microneedle patch in high-fat diet-induced obese C57BL/6J mice10.1016/j.jconrel.2017.03.400 ↗
32. Design, optimization and characterisation of polymeric microneedle arrays prepared by a novel laser-based micromoulding technique10.1007/s11095-010-0169-8 ↗
33. Bioresponsive microneedles with a sheath structure for H2O2 and pH cascade-triggered insulin delivery
34. Poly-gamma-glutamic acid microneedles with a supporting structure design as a potential tool for transdermal delivery of insulin10.1016/j.actbio.2015.06.021 ↗
35. Effect of microneedle type on transdermal permeation of rizatriptan10.1208/s12249-016-0702-0 ↗